{
    "nct_id": "NCT06657183",
    "official_title": "Enhanced Care Management (ECM) and Continuous Monitoring of Vital Signs With Alio Smart Patch Wearable Sensor in Adult Cancer Patients Receiving Chemotherapy With Moderate or High Risk of Febrile Neutropenia or Immunotherapy",
    "inclusion_criteria": "* Individuals must meet all of the following inclusion criteria in order to be eligible to participate in the study:\n* Subjects have a diagnosis of soft tissue sarcoma, NSCLC, HNSCC, breast, pancreatic cancer, or melanoma\n* For Cohort 1 (n=15), participants are eligible if starting on a new chemotherapy regimen with either: (i) high risk (> 20%) of febrile neutropenia as per NCCN MGF guidelines; or (ii) intermediate risk for febrile neutropenia AND one or more risk factors for febrile neutropenia:\n\n  * Age > or equal to 65 years\n  * Advanced disease\n  * Previous Chemotherapy or Radiation therapy\n  * Preexisting neutropenia or bone marrow involvement with tumor\n  * Infection\n  * Open wounds or surgery in last 4 weeks\n  * Poor performance status or poor nutritional status\n  * Poor renal function (cr clearance <50)\n  * Total Bilirubin >1.5 upper limit of normal\n  * Cardiovascular Disease\n  * Multiple Co-morbidities\n  * HIV infection\n  * BMI > 2.0\n* For Cohort 2 (n=15) participants are eligible if starting on immunotherapy alone, or concurrent chemo-immunotherapy.\n* Participants are capable of giving informed consent\n* Participants must be able to read and/or to speak English\n* Participants who are 18 years of age or older\n* Expected chemotherapy treatment duration of at least 12 weeks\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* An individual who meets any of the following criteria will be excluded from participation in this study:\n\n  * Participants who cannot read or speak English\n  * Participants without any cellphone access",
    "miscellaneous_criteria": ""
}